Global Trial in APG2575 for Patients With CLL/SLL
← catalyst calendarNCT06104566 · readout in 134 d
Sponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
400estimated
Sites
135
Countries
Australia, Belgium, Bulgaria +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-20 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- CLL/SLL
Interventions
- Drug: lisaftoclax +BTK inhibitor
- Drug: BTK inhibitor
Primary outcome
what the primary-completion date above is the date OFPFS
measured 12 months
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed